BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Ajanta Pharma Ltd. delivered a miss on operational performance in Q2 FY23, led by higher employee and freight costs. Adverse currency movement in Africa branded generics and price erosion in U.S. generics affected profitability in Q2 FY23.
Branded generics in India (domestic formulation) and Asia witnessed robust industry outperformance in Q2 FY23.
We have cut our FY23/FY24 estimate by 6%/5% to factor in:
a lack of launches in U.S. generics,
moderation in its growth prospects in the Africa business due to currency headwinds, and
elevated raw material and logistics cost.
While there are near-term headwinds on the opex front, Ajanta Pharma remains well placed to deliver better-than-industry sales growth in the branded generics segment of domestic formulation, Asia, and Africa. After the successful compliance at Dahej, abbreviated new drug application approvals are also expected to gather pace.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.